Developing mutant TP53-targeted immunotherapies for difficult-to-treat cancers, beginning with pancreatic cancer.
Developing mutant TP53-targeted immunotherapies for difficult-to-treat cancers, beginning with pancreatic cancer.
Engineered T cell receptor programs designed to recognize shared TP53 mutations expressed in solid tumors.
Initial development focuses on autologous TCR- T approaches translated through controlled preclinical validation.
Scientific execution is supported through academic collaboration and laboratory- based therapeutic development.
Long-term development includes next-generation delivery and engineering strategies for broader solid tumor applications.
OncoVanta Therapeutics is a biotechnology company focused on engineered T cell therapies designed to target shared cancer mutations in solid tumors.
Initial scientific development centers on mutant TP53- directed TCR programs translated through academic collaboration focused on controlled preclinical therapeutic development.
Roman Owens is Founder and Chief Executive Officer of OncoVanta Therapeutics, where he leads corporate strategy, licensing execution, translational development planning, and strategic partnerships for the company’s mutant TP53-targeted TCR-T platform. He serves as primary liaison for NIH licensing activities and oversees alignment of scie
Roman Owens is Founder and Chief Executive Officer of OncoVanta Therapeutics, where he leads corporate strategy, licensing execution, translational development planning, and strategic partnerships for the company’s mutant TP53-targeted TCR-T platform. He serves as primary liaison for NIH licensing activities and oversees alignment of scientific development, financing strategy, and long-term commercialization planning.
He brings experience in regulated systems environments, financial planning, and technical execution, supporting disciplined progression of early-stage oncology programs. Under his leadership, OncoVanta has established its scientific team, academic collaborations, and staged development pathway toward preclinical proof-of-concept.
Dr. Hudson is a translational oncology scientist with expertise in cancer biology and biomarker-driven research strategy. As Chief Scientific Officer, he provides scientific oversight for research planning, experimental direction, and translational alignment across OncoVanta’s preclinical oncology programs.
He also serves on the Board, hel
Dr. Hudson is a translational oncology scientist with expertise in cancer biology and biomarker-driven research strategy. As Chief Scientific Officer, he provides scientific oversight for research planning, experimental direction, and translational alignment across OncoVanta’s preclinical oncology programs.
He also serves on the Board, helping guide scientific governance and long-term therapeutic development strategy.
Dr. Zhang leads TCR engineering, immune assay development, and preclinical execution of OncoVanta’s TP53 R175H TCR-T program. Her work focuses on cellular immunology, functional cytotoxicity testing, and generation of translational datasets that support advancement toward IND-enabling studies.
She directs experimental design and scientific
Dr. Zhang leads TCR engineering, immune assay development, and preclinical execution of OncoVanta’s TP53 R175H TCR-T program. Her work focuses on cellular immunology, functional cytotoxicity testing, and generation of translational datasets that support advancement toward IND-enabling studies.
She directs experimental design and scientific interpretation across the company’s early-stage cell therapy platform.
Dr. Akala is a Professor of Pharmaceutics with extensive NIH-funded research experience in nanomedicine, controlled drug delivery, and translational pharmaceutical sciences. At OncoVanta, he advises on long-term delivery innovation and platform expansion strategies that may strengthen future therapeutic formats.
His expertise supports eval
Dr. Akala is a Professor of Pharmaceutics with extensive NIH-funded research experience in nanomedicine, controlled drug delivery, and translational pharmaceutical sciences. At OncoVanta, he advises on long-term delivery innovation and platform expansion strategies that may strengthen future therapeutic formats.
His expertise supports evaluation of advanced drug delivery technologies complementary to the company’s immunotherapy platform.
Joyce Terry provides operational leadership across grant coordination, documentation workflows, external communications, and development program readiness. She supports continuity across scientific operations, administrative planning, and regulatory preparation.
Her background includes more than 25 years of experience in organizational leadership, grant writing, and compliance oversight.